New Study Highlights Efficacy of IpsiHand® in Enhancing Motor Function After Stroke

Introduction

In a significant breakthrough for stroke recovery, Kandu, Inc. has unveiled findings from its study, revealing that the IpsiHand® system, a brain-computer interface (BCI) technology, greatly improves motor function in post-stroke patients. This pioneering research is featured in the prestigious journal, Stroke: Vascular and Interventional Neurology, and represents the first randomized controlled trial focusing on at-home, noninvasive BCI therapy for chronic stroke survivors.

Study Overview

Conducted as part of the BCI-REHAB initiative, the study aimed to determine how effective the IpsiHand® is in improving upper extremity functionality when utilized outside clinical settings. A total of 62 participants, who had suffered strokes at least six months prior, engaged in the therapy program over 12 weeks. Participants were required to use the IpsiHand® system for one hour a day, five days a week, without any in-clinic visits.

Eric C. Leuthardt, MD, Kandu’s Chief Scientific Officer and the principal investigator, highlighted the remarkable outcomes: "This is the first randomized trial to show that engaging preserved ipsilateral neural signals through a noninvasive brain-computer interface can drive clinically meaningful motor recovery in chronic stroke."

Results and Impact

The study yielded impressive results; patients using the IpsiHand® experienced a 6.0 point overall gain in the Upper Extremity Functioning Measure score, indicating a level of improvement significantly surpassing the established Minimal Clinically Important Difference (MCID). Furthermore, a noteworthy 55.5% of participants in the IpsiHand group achieved clinically meaningful improvements within the 12-week span, compared to only 9.6% in the control group, demonstrating a stark contrast.

Mechanism of Action

The IpsiHand® system operates by pairing a noninvasive EEG headset with a wearable handpiece. When the device detects a patient's intention to move their impaired hand, the handpiece responds in near real-time to assist movement, thus reinforcing the relevant neural pathways and facilitating recovery. This approach leverages the concept that motor-intent signals from the unaffected hemisphere may still persist post-stroke, offering a novel rehabilitation avenue for individuals struggling with upper extremity deficits.

Future Directions

Leo Petrossian, PhD, CEO of Kandu, emphasized the transformational potential of these findings, stating, "Publication in this prestigious journal is exactly the kind of evidence that changes how a therapy is viewed and adopted." He further remarked that this study strengthens the existing body of evidence supporting the therapeutic benefits of the IpsiHand® device.

Conclusion

The research findings underscore a promising advancement in stroke rehabilitation, positioning the IpsiHand® as a valuable tool in restoring motor function to survivors. As Kandu, Inc. continues to advocate for increased adoption of BCI technology in therapeutic settings, the hope exists that stroke patients who were previously told that recovery was unlikely may find renewed possibilities through evidence-based methods. The full study is available via open access in the aforementioned journal, offering keen insights for researchers and practitioners alike.

For more information about Kandu and its innovative approaches to stroke recovery, visit kandu.com.